跳至主要内容
临床试验/EUCTR2006-005754-80-SE
EUCTR2006-005754-80-SE进行中(未招募)不适用

Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study. - The STING 2 study

Karolinska University Hospital0 个研究点目标入组 128 人开始时间: 2007年8月24日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histologically verified diagnosis of small cell lung cancer
  • Limited disease as stage I,II or III
  • Performance status <= 2
  • Leukocyte count (LPC) > 3 * 10(9)/L
  • Thrombocyte count (TPC) > 100*10(9)/L
  • ASAT/ALAT < 3 * normal value
  • Crreatinine < 1.5 * normal value
  • Age 18-75 years
  • Formerly untreated patients
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Serious heart disease, kidney disease, impaired lung function or other disease which may pose risk to standard treatment
  • Reduced ability to cooperate
  • Performance status 3 and 4
  • History of malignant disease other than basal cell carcinoma or stage I cancer of the cervix
  • Pregnant or breast feeding

研究者

发起方
Karolinska University Hospital

相似试验